FDA Approval Status Update for Calcium Acetate by Chartwell Molecular
The FDA has granted an Approval Pending (AP) status for ANDA202420, a supplemental application for Calcium Acetate submitted by Chartwell Molecular.
Therapeutic Area
Therapeutic area intelligence for Renal with 2 indexed intelligence signals across regulatory, clinical, competitive, and market developments.
No related entities indexed yet.
No catalysts indexed for this entity yet.
No related entities indexed yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.